Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun;70(6):896-904.
doi: 10.1136/ard.2011.151027.

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

J Braun  1 , R van den Berg, X Baraliakos, H Boehm, R Burgos-Vargas, E Collantes-Estevez, H Dagfinrud, B Dijkmans, M Dougados, P Emery, P Geher, M Hammoudeh, R D Inman, M Jongkees, M A Khan, U Kiltz, Tk Kvien, M Leirisalo-Repo, W P Maksymowych, I Olivieri, K Pavelka, J Sieper, E Stanislawska-Biernat, D Wendling, S Ozgocmen, C van Drogen, Bj van Royen, D van der Heijde
Affiliations

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

J Braun et al. Ann Rheum Dis. 2011 Jun.

Abstract

This first update of the ASAS/EULAR recommendations on the management of ankylosing spondylitis (AS) is based on the original paper, a systematic review of existing recommendations and the literature since 2005 and the discussion and agreement among 21 international experts, 2 patients and 2 physiotherapists in a meeting in February 2010. Each original bullet point was discussed in detail and reworded if necessary. Decisions on new recommendations were made - if necessary after voting. The strength of the recommendations (SOR) was scored on an 11-point numerical rating scale after the meeting by email. These recommendations apply to patients of all ages that fulfill the modified NY criteria for AS, independent of extra-articular manifestations, and they take into account all drug and non-drug interventions related to AS. Four overarching principles were introduced, implying that one bullet has been moved to this section. There are now 11 bullet points including 2 new ones, one related to extra-articular manifestations and one to changes in the disease course. With a mean score of 9.1 (range 8-10) the SOR was generally very good.

PubMed Disclaimer

Conflict of interest statement

Competing interests None.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442–52 - PMC - PubMed
    1. Zhang W, Doherty M, Bardin T, et al. ; for the EULAR Standing Committee for International Clinical Studies Including Therapeutics EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312–24 - PMC - PubMed
    1. Mukhtyar C, Guillevin L, Cid MC, et al. ; for the European Vasculitis Study Group EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310–17 - PubMed
    1. Landewé RB, Günther K, Lukas C, et al. EULAR/EFORT recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee. Ann Rheum Dis 2010;69:12–19 - PubMed
    1. Kowal-Bielecka O, Landewé R, Avouac J, et al. ; EUSTAR Co-Authors EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620–8 - PubMed

Publication types

MeSH terms

Substances